Ph.D. Noubar B. Afeyan - 26 Oct 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
Issuer symbol
MRNA
Transactions as of
26 Oct 2022
Net transactions value
-$1,372,500
Form type
4
Filing time
28 Oct 2022, 19:30:10 UTC
Previous filing
21 Oct 2022
Next filing
04 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale $1,372,500 -10,000 -0.42% $137.25 2,357,209 26 Oct 2022 Direct F1
holding MRNA Common Stock 12,882,819 26 Oct 2022 By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. F2
holding MRNA Common Stock 3,924 26 Oct 2022 By Flagship Pioneering, Inc. F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021, as amended on March 11, 2022.
F2 10,801,059 shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and 2,081,760 shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.